Traditional Chinese medicine study for idiopathic pulmonary fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This study follows people with idiopathic pulmonary fibrosis (IPF) to learn how traditional Chinese medicine may help. By joining, you help researchers understand better ways to manage this lung condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of idiopathic pulmonary fibrosis (IPF).
- You must be at least 40 years old.
- You must be willing to take part and sign a consent form.
- You must not have confusion, dementia, or other mental health conditions that affect decision-making.
- You must be able to care for yourself and not be bedridden for a long time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the symptoms and patterns of idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. By joining, you help doctors better understand the disease, which may lead to better care.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
This trial tests a new drug called TDI01 to see if it helps people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. You may qualify if you have a confirmed IPF diagnosis and your lung function is stable enough.
This trial tests an inhaled drug called LTI-03 to see if it can help people with idiopathic pulmonary fibrosis (IPF). It may be an option for those with moderate lung function who are stable on their current treatment.
This study looks at genetic (inherited) factors related to pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF). It may help researchers understand why some families are more affected and could guide future testing or treatments.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.